Information Library

Results for: Lower portfolio & investment risks - Product Development & Commercialization

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Biomarkers in Alzheimers Disease

    Presentation — March 17, 2011
    The Quintiles Innovation Unit shares their knowledge on the use of biomarkers in compound development in clinical trials.

  • Consulting – Breakthrough Thinking Built on Experience

    Brochure — November 23, 2010
    Consulting at Quintiles brings a critical element to engagements: fresh thinking built on a full lifecycle understanding of biopharma realities today.

  • Safety Strategy & Optimization

    Brochure — September 14, 2010
    Learn how to enable your safety group to become a value-added contributor throughout the product lifecycle.

  • Managing Pharmacovigilance as a Business

    White Paper — July 28, 2010
    The three steps required to develop a strategic approach to global capacity management.

  • Rebalancing Risk to Transform R&D

    White Paper — June 3, 2009
    A strategic approach to re-balancing the main components of biopharma company risk: portfolio, operational and resource.

  • Adrian McKemey, Ph.D.

    Hear from the Experts — March 25, 2009
    Adrian leads the Product Development and Commercialization consulting practice at Quintiles Global Consulting.

  • Jim Featherstone, Ph.D.

    Hear from the Experts — March 25, 2009
    Jim joined Quintiles Consulting from Wood Mackenzie, a leading business intelligence and strategy consulting services company based in the UK, where he was the Global Head of Consulting for the Pharmaceuticals and Biotechnology practice.

  • Jay Norman

    Hear from the Experts — March 24, 2009
    President – Quintiles Consulting Jay brings 25 years of experience in the consulting industry and a strong track record of growth, most recently with Diamond Management and Technology Consultants, where he served as President and Chief Operating Officer.

  • Podcast: A New Gold Standard

    Hear from the Experts — May 1, 2008
    John Doyle discusses the concept of a health economic balance sheet and the need for evidence-based pricing for biopharmaceutical valuation.

Page 1 of 1 (9 results)

Subscribe to Email Based on Your Interests

Set preferences